Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy
November 11 2021 - 8:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the
Company), a novel biotechnology company focused on the research and
discovery of new and effective treatments for psychiatric and
neurological disorders, today announced that its wholly owned
subsidiary Pasithea Clinics, has entered into a collaboration with
the internationally renowned musician and producer DJ Carlita, to
create customized music playlists to accompany patients’
intravenous (IV) ketamine infusion therapy sessions.
“Music has long been recognized as an integral
part of psychedelic therapy, and many world-leading research
centers such as Johns Hopkins and Imperial College use specific
playlists in their clinical trials. We are committed to creating an
optimal experience for our ketamine infusion patients as there is
strong evidence to support the effect of music in improving
clinical outcomes. Music and psychedelic therapy are true
complements, and through our collaboration with DJ Carlita, we aim
to improve the overall experience for our patients,” stated Dr.
Tiago Reis Marques, CEO of Pasithea Therapeutics.
Carlita is a classically trained musician,
graduated in cello from the Royal Academy of Music in London. She
has since evolved to become a producer and DJ, having played on the
most important stages internationally since her debut. She is known
to combine an ever-changing kaleidoscope of sounds and cultures
with electronic music and has been particularly involved in
producing music for sound healing experiences around the world. “My
music is known to create strong emotional experiences and I could
not be more enthusiastic with this collaboration. I used my
expertise on sound healing to produce music sets lasting the
duration of the ketamine treatment, using specific sounds and
rhythms to create a therapeutic environment where patients can
journey through their emotions and memories in a unique way.”
Pasithea Clinics, a wholly owned subsidiary of
Pasithea Therapeutics, recently opened its first ketamine therapy
clinic in the United Kingdom and began administering intravenous
ketamine therapy to patients. In the United States, Pasithea will
provide in-home IV ketamine treatments.
Ketamine is a U.S. Food and Drug Administration
(“FDA”) approved drug introduced as an anesthetic more than 50
years ago. It has recently been repurposed in significantly lower
doses for the treatment of psychiatric disorders and is now gaining
ground as a promising treatment for mental health disorders. In
certain psychiatric conditions, such as treatment-resistant
depression (“TRD”), bipolar depression and post-traumatic stress
disorder (“PTSD”), it has shown remarkable efficacy and a rapid and
sustained effect.
About Pasithea Therapeutics
Corp.
Pasithea Therapeutics Corporation is a U.S.
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders. With an experienced team of experts in the fields of
neuroscience and psychopharmacology, Pasithea is developing new
molecular entities for the treatment of psychiatric and
neurological disorders. Pasithea is also focused on addressing the
needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company ContactDr.
Tiago Reis MarquesChief Executive OfficerE: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
RelationsLisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Apr 2023 to Apr 2024